• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Chin Med J (Engl). Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

tetano

Editor, Senior Moderator
Chin Med J (Engl). 2020 Mar 20. doi: 10.1097/CM9.0000000000000824. [Epub ahead of print]
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study.


Deng Y[SUP]1[/SUP], Liu W[SUP]2[/SUP], Liu K[SUP]1[/SUP], Fang YY[SUP]1[/SUP], Shang J[SUP]1[/SUP], Zhou L[SUP]1[/SUP], Wang K[SUP]1[/SUP], Leng F[SUP]1[/SUP], Wei S[SUP]1[/SUP], Chen L[SUP]1[/SUP], Liu HG[SUP]1[/SUP].

Author information




Abstract

BACKGROUND:

The 2019 novel coronavirus (2019-nCoV) has caused the outbreak of the acute respiratory disease in Wuhan, Hubei Province of China since December 2019. This study is performed to analyze the clinical characteristics of patients who succumbed to and who recovered from 2019 novel coronavirus disease (COVID-19).
METHODS:

Clinical data were collected from two tertiary hospitals in Wuhan. A retrospective investigation was conducted to analyze the clinical characteristics of fatal cases of COVID-19 (death group) and compare them with recovered patients (recovered group). Continuous variables were analyzed using the Mann-Whitney U test. Categorical variables were analyzed by χ test or Fisher's exact tests as appropriate.
RESULTS:

Our study enrolled 109 COVID-19 patients who died during hospitalization and 116 recovered patients. The median age of the death group was older than the recovered group (69 [62, 74] years vs. 40 [33, 57] years, Z = 9.738, P < 0.001). More patients in the death group had underlying diseases (72.5% vs. 41.5%, χ = 22.105, P < 0.001). Patients in the death group had a significantly longer time of illness onset to hospitalization (10.0 [6.5, 12.0] days vs. 7.0 [5.0, 10.0] days, Z = 3.216, P = 0.001). On admission, the proportion of patients with symptoms of dyspnea (70.6% vs. 24.7%, χ = 60.905, P < 0.001) and expectoration (32.1% vs.15.7%, χ = 13.250, P < 0.001) was significantly higher. The blood oxygen saturation was significantly lower in the death group (85 [77, 91]% vs. 97 [95, 98]%, Z = 10.625, P < 0.001). The white blood cell (WBC) in death group was higher on admission (7.23 [4.87, 11.17] ? 10/L vs. 4.52 [3.62, 5.88] ? 10/L, Z = 7.618, P < 0.001). Patients in the death group exhibited significantly lower lymphocyte count (0.63 [0.40, 0.79] ? 10/L vs. 1.00 [0.72, 1.27] ? 10/L, Z = 8.037, P < 0.001) and lymphocyte/WBC ratio (7.10 [4.45, 12.73]% vs. 23.5 [15.27, 31.25]%, Z = 10.315, P < 0.001) on admission, and the lymphocyte/WBC ratio continue to decrease during hospitalization (7.10 [4.45, 12.73]% vs. 2.91 [1.79, 6.13]%, Z = 5.242, P < 0.001). Alanine transaminase (ALT) (22.00 [15.00, 34.00] U/L vs. 18.70 [13.00, 30.38] U/L, Z = 2.592, P = 0.010), aspartate transaminase (AST) (34.00 [27.00, 47.00] U/L vs. 22.00 [17.65, 31.75] U/L, Z = 7.308, P < 0.001), and creatinine levels (89.00 [72.00, 133.50] μmol/L vs.65.00 [54.60, 78.75] μmol/L, Z = 6.478, P < 0.001) were significantly higher in the death group that those in the recovered group. C-reactive protein (CRP) levels were also significantly higher in the death group on admission (109.25 [35.00, 170.28] mg/L vs.3.22 [1.04, 21.80] mg/L, Z = 10.206, P < 0.001) showed no significant improvement after treatment (109.25 [35.0, 170.28] mg/L vs. 81.60 [27.23, 179.08] mg/L, Z = 1.219, P = 0.233). The patients in the death group had more complications such as acute respiratory distress syndrome (89.9% vs. 7.6%, χ = 148.105, P < 0.001), acute cardiac injury (59.6% vs. 0.8%, χ = 93.222, P < 0.001), acute kidney injury (18.3% vs. 0, χ = 23.257, P < 0.001), shock (11.9% vs. 0, χ = 14.618, P < 0.001), and disseminated intravascular coagulation (DIC) (6.4% vs. 0, χ = 7.655, P = 0.006).
CONCLUSIONS:

Compared to the recovered group, more patients in the death group exhibited characteristics of advanced age, pre-existing comorbidities, dyspnea, oxygen saturation decrease, increased WBC count, decreased lymphocytes, and elevated CRP levels. More patients in the death groups had complications such as ARDS, acute cardiac injury, acute kidney injury, shock, and DIC.



PMID:32209890DOI:10.1097/CM9.0000000000000824
 
Back
Top